* In Ph2, Lower dose was more efficacious than higher dose * Ph2 subjects were highly un-uniform * Several deaths occurred in Ph 2 subjects. Deaths occurred in Bangladesh, Sri Lanka, Philz & Russia
Timeline:
* Rolling NDA submission begin in 2018 * Ph3 data is expected in Q4 1019 * Cash runway into 2020 * Earliest approval would be late 2020
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.